Using cell cultures, German researchers show how the drug may regulate the energy balance in damaged body cells
A diabetes drug might help in certain types of Parkinson’s disease, reports a team of German brain researchers headed by Dr. Julia Fitzgerald at the Hertie Institute for Clinical Brain Research, the University of Tübingen and the German Center for Neurodegenerative Diseases in Tübingen.
The neuroscientists identified a protein that plays an important role in the energy balance of cells. If the protein is missing, the energy balance is disturbed leading possibly to cell death and ultimately to the onset of the disease.
In Parkinson’s disease, nerve cells die off in a brain area responsible for movement control. Using cell cultures, the research team has now shown that the diabetes drug metformin acts on the energy budget, thereby protecting the cells. The study has been published in the current issue of the journal Brain.
“When studying cells from a patient suffering from Parkinson’s disease we saw that they lack an important protein which regulates the energy production,” explains Fitzgerald. As a result, the cells keep on producing energy in their mitochondria—the cells’ powerhouses—unchecked and less regulated.
Energy production comes at the cost of the generation of free oxygen radicals. The radicals damage the cell and lead to aging and, in the long term, sometimes to cell death. “The diabetes drug acts like a brake in this process. It slows down the uncontrolled generation of energy, thereby protecting the cells from the negative effects,” the researcher reports.
The study by the Tübingen neuroscientists provides another indication that diabetes drugs might have a positive influence on certain types of Parkinson’s disease. “Only recently, an Anglo-American research collaboration showed that another diabetes drug can reduce movement disorder symptoms in patients with Parkinson’s disease,” says Fitzgerald.
The new findings of Fitzgerald and her colleagues contribute to the development of personalized medicine which aims at treating the disease with interventions tailored to the underlying individual trigger factor in each patient. In Parkinson’s disease, both hereditary predisposition and environmental influences play a role in the development of the disease.
“Ultimately, the cause varies from person to person,” explains Fitzgerald. “In the long term, our study will be beneficial to patients suffering from faulty energy production in cells.” At present, there are no drugs available that may stop or slow down Parkinson’s disease, physicians may only treat symptoms. Worldwide, there are about 10 million people affected by the
Fitzgerald et al. (2017): Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson’s disease. Brain 140(9), pp 2444–2459.
Dr. Julia Fitzgerald
Hertie Institute for Clinical Brain Research
University of Tübingen
Phone: +49 7071 29-87616
Dr. Mareike Kardinal | idw - Informationsdienst Wissenschaft
Could this protein protect people against coronary artery disease?
17.11.2017 | University of North Carolina Health Care
Microbial resident enables beetles to feed on a leafy diet
17.11.2017 | Max-Planck-Institut für chemische Ökologie
The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.
Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...
Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.
That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...
Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.
During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....
The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.
Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...
Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...
15.11.2017 | Event News
15.11.2017 | Event News
30.10.2017 | Event News
17.11.2017 | Physics and Astronomy
17.11.2017 | Health and Medicine
17.11.2017 | Studies and Analyses